The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...

PFS significantly higher with nivolumab, doxorubicin, vinblastine, and dacarbazine versus brentuximab vedotin-AVD.

CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...

This article is authored by Dr Amrit Kaur Kaler, consultant, molecular pathology, Kokilaben Dhirubhai Ambani Hospitals, ...

Chugai files regulatory application with MHLF for additional indication of Tecentriq to treat adjuvant therapy for MRD-positive bladder cancer: Tokyo Thursday, January 29, 2026, 0 ...

US FDA grants orphan drug designation to Imviva Biotech’s CTD402 for the treatment of T-cell leukaemia and lymphoma: Boston Friday, January 30, 2026, 17:00 Hrs [IST] Imviva Biot ...

ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...

Frigid temperatures and residual snow from Winter Storm Fern couldn’t stop musicians from across the country from attending Saturday’s Open Jam session at downtown Owensboro’s Bluegrass Music Hall of ...

Cash-rich Cullinan Therapeutics stock: zipalertinib NDA in Q1 2026 plus CLN-978 and CLN-049 AML catalysts. Read here for more analysis.

February is National Cancer Prevention Month—a critical time to focus on reducing occupational exposures that contribute to elevated cancer risk among firefighters.

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...